This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Feola, D. J. Articles by Garvy, B. A. Search for Related Content PubMed PubMed Citation Articles by Feola, D. J. Articles by Garvy, B. A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2006, p. 193-201, Vol. 13, No. 2
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.2.193-201.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Combination Exposure to Zidovudine plus Sulfamethoxazole-Trimethoprim Diminishes B-Lymphocyte Immune Responses to Pneumocystis murina Infection in Healthy Mice

Department of Pharmacy Practice and Science, University of Kentucky Chandler Medical Center, Lexington, Kentucky,¹ Departments of Microbiology, Immunology, and Molecular Genetics and Internal Medicine Division of Infectious Diseases, University of Kentucky Chandler Medical Center, and Veterans Administration Medical Center, Lexington, Kentucky²

Received 24 August 2005/ Returned for modification 24 October 2005/ Accepted 9 November 2005

We have previously shown that zidovudine plus sulfamethoxazole-trimethoprim exposure decreases immune cell populations in the bone marrow of healthy mice by inducing apoptosis. The hypothesis of the current work was that this toxicity would have an adverse impact on the immune response. To determine this, BALB/c mice were treated with zidovudine, sulfamethoxazole-trimethoprim, the combination of both drugs, or vehicle only (control) via oral gavage for 21 days. On day 4 after dosing completion, the mice were infected intratracheally with 1 x 10⁷ Pneumocystis murina organisms. Immune cell populations (in lung digest, bronchoalveolar lavage fluid, tracheobronchial lymph node, and bone marrow samples), the lung Pneumocystis burden, and serum Pneumocystis-specific antibody titers were determined at days 6, 10, and 20 postinfection. While total bone marrow cellularity was recovered by day 6 postinfection in the combination exposure group, B-cell numbers did not recover until 10 days postinfection, primarily due to the persistent depletion of the late pre-B-cell phenotype. The numbers of CD4⁺ and CD8⁺ T cells, as well as the numbers of total B cells and activated B cells in tracheobronchial lymph nodes, were decreased at days 10 and 20 as a result of zidovudine plus sulfamethoxazole-trimethoprim exposure compared to the numbers in the control group. No significant differences in lung lavage or lung digest cell populations were observed. There was a trend of a delay in Pneumocystis clearance in the combination treatment group, and Pneumocystis-specific serum immunoglobulin G titers were reduced at day 20 postinfection. Together, these data indicate that the combination of zidovudine and sulfamethoxazole-trimethoprim adversely affects the humoral immune response to Pneumocystis.